Gain Therapeutics
GANX
42 hedge funds and large institutions have $15.8M invested in Gain Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 16 closing their positions.
402% more call options, than puts
Call options by funds: $502K | Put options by funds: $100K
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
4% less capital inflows, than outflows
Capital inflows: $1.86M | Capital outflows: $1.94M
1.55% less ownership
Funds ownership: 20.95% → 19.4% (-1.6%)
13% less funds holding
Funds holding: 48 → 42 (-6)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
+$635K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$303K |
| 3 |
Stratos Wealth Partners
Beachwood,
Ohio
|
+$286K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$234K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$551K |
| 2 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$251K |
| 3 |
HRT Financial
New York
|
-$179K |
| 4 |
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$120K |
| 5 |
Goldman Sachs
New York
|
-$105K |
GANX Hedge Fund Activity: Q1 2026 in Review
42 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2026, worth a combined $15.8M — down 39% from $25.9M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GANX and 7 opened new positions — a net loss of 9 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was GSA Capital Partners, adding an estimated $635K. The largest seller was Susquehanna International Group, cutting an estimated $551K.
- 42 institutional investors held Gain Therapeutics (GANX) as of Q1 2026, down from 48 in Q4 2025.
- Funds reported $15.8M of Gain Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
- 7 funds opened new Gain Therapeutics positions in Q1 2026 and 16 closed out, a net change of -9 holders.
- The largest Gain Therapeutics buyer in Q1 2026 was GSA Capital Partners, an estimated $635K added.
- The largest Gain Therapeutics seller in Q1 2026 was Susquehanna International Group, an estimated $551K sold.
Based on aggregated 13F filings for Q1 2026.